In a report released today, Florent Cespedes from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Minnesota Attorney General Keith Ellison on Monday announced a settlement in a lawsuit against insulin manufacturer Novo Nordisk. Minnesota residents will now be able to get Novo Nordisk insulin ...

While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...

Novo Nordisk’s CEO toasted the company’s record-breaking profitability and earnings on Wednesday morning as the group behind Ozempic and Wegovy put on a brave face about its ability to fight ...

Ellison says the agreement requires Denmark-based manufacturer Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month for the next five years, even for people without health ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...

Novo Nordisk A/S Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...

Novo Nordisk reported $40.5 billion in sales for 2024, surpassing Wall Street’s expectations. Its success was driven by its two GLP-1 drugs, Ozempic and Wegovy. The company is in a race with ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...